anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Rationale: Interferon has long been used as a therapy for renal cell carcinoma. However, optimal dosing schedules have not been identified and patients have been relegated to receiving the highest possible doses for prolonged periods of time. This high-dose approach often leads to serious adverse effects from toxicity that limits the usefulness and patient tolerance of this treatment. No formal study has determined the relationship if any between the maximal tolerated dose (MTD) and the biological effective dose of interferon alpha-2b. The current study seeks to fill that gap by gathering research information about different doses of interferon alpha-2b and correlating with measurements of JAK/STAT in the blood. Validation of correlative studies to determine optimum biologic dosing are needed so that therapy may be adjusted appropriately rather then the current approach of maximizing dose. In addition, a trial of low dose daily administered interferon-2b has not been carried out in the current era with refined histologic classification and modern CT imaging scanning. As this therapy potentially has wide applicability, definite response rates need to be documented.

Purpose: The purpose of this study is to assess the response rate of daily low dose interferon-2b in patients with metastatic or unresectable clear cell renal carcinoma. The duration of the response and overall survival will be determined in study participants. This study will also evaluate JAK/STAT, two types of kinases or enzymes involved in an intracellular signaling process associated with cancer growth, in peripheral blood mononuclear cells over the course of interferon alpha-2b dose escalation. Researchers will examine in a preliminary manner the correlation between clinical response, toxicity, and JAK/STAT signal transduction. Progression free survival and rate of stable disease will also be determined in a preliminary manner.

Treatment: Study participants will receive interferon alpha-2b. This drug will be self-administered daily through injections into the skin. The dose level of interferon alpha-2b will be increased each week into study treatments. For the first three weeks and approximately monthly thereafter, patients will have blood drawn three hours following interferon alpha-2b administration to measure JAK/STAT. Toxicity from study treatments will be closely monitored in patients during clinics visits. Supportive care therapies will be given throughout the study. Treatments will be discontinued due to disease growth or unacceptable side effects.
Participants will be given letrozole 10mg daily for one week after standard medical management for tubal ectopic pregnancy by methotrexate injection. Subsequently they will receive the standard management for medical management of tubal ectopic prengnacies.
Invention relates to veterinary preparations for stimulating non-specific immunity in animals. The invention describes a method for producing the preparation from dog placenta. The method provides for cutting into small pieces, washing in distilled water and physiological solution, homogenising and incubating at +40C dog placenta. Further steps of the method are: separation of liquid phase, e.g., by centrifugation, incubation of supernatant at - 200C temperature, filtering and freeze drying. The preparation obtained stimulates activity of monocytes and phagocytes. It exhibits antitumor activity.
Disclosed are medicinal liquor and preparation technology. Raw materials of the medicinal liquor comprise 67 kinds of traditional Chinese medicinal materials. According to the preparation technology of the medicinal liquor, full extraction of effective constituents of the original medicinal materials can be guaranteed. Tastes of the medicinal liquor are improved. The medicinal liquor has the advantages of being pure, mild and soft. Technology of igniting liquid medicine and reducing alcohol content in a bronze tripod is adopted, thus micromolecule organic substances volatilize and burn. Harmful effects of the substances on the function of a human body are reduced. Buried technology of pottery-jar containing the liquid medicine is adopted, various probiotics and functional materials are formed through the fermentation of the medicinal liquor, and thus a unique odor type and a special flavour are formed.
Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are the most severe cutaneous adverse reactions that are typically drug-induced in adults. Both SJS and TEN have high morbidity and mortality rates. SJS/TEN imposes clinical challenges for physicians managing patients suffering from this condition, both because it is rare and because it is a rapidly progressing systemic disease with severe cutaneous, mucosal, and systemic manifestations. Although many cases of SJS/TEN have been reported in the literature, there is no consensus regarding diagnostic criteria or treatment. Significant progress has been made in understanding its genetic predisposition and pathogenesis. This review is intended to provide physicians with a comprehensive but practical SJS/TEN roadmap to guide diagnosis and management. We review data on pathogenesis, reported precipitating factors, presentation, diagnosis, and management SJS/TEN focusing on what is new over the last 5 years.
We report a case of corneal epithelial hyperplasia associated with chronic eye rubbing mimicking keratoconus. A 32-year-old man was presented with a 3-year history of suboptimal vision and astigmatism in his left eye. His history was significant for chronic left eye rubbing. The anterior corneal curvature map showed inferior steepening in the left eye; however, other features of ectasia were absent. Corneal epithelium thickness mapping with optical coherence tomography was significant for corresponding epithelial thickening. His corneal imaging remained stable at a 6-month follow-up examination. At month 15-and after cessation of eye rubbing behavior-the vision symptoms, refraction, and corneal imaging had normalized. In conclusion, chronic eye rubbing may cause reversible corneal epithelial hypertrophy. Eye rubbing should be considered in the evaluation of patients presenting with unexplained vision symptoms and changes in astigmatism that are not consistent with ectasia on corneal imaging.
1462805 Fortimicin B ABBOTT LABORATORIES and KYOWA HAKKO KOGYO CO Ltd 16 April 1974 [17 April 1973] 16569/74 Headings C2A and C2C A process for producing the antibiotic Fortimicin B comprises culturing a microorganism belonging to the genus Micromonospora having the ability to produce Fortimicin B in a nutrient medium and accumulating Fortimicin B in said medium. Suitable microorganisms are Micromonospora olivoasterospora ATCC 21819, Micromonospora olivoasterospora ATCC 31009 and Micromonospora olivoasterospora ATCC 31010. Fortimicin B has a molecular weight of 348, a formula of C 15 H 32 N 4 O 5 ,a melting point of 101-103 C., an optical rotation [α] D <SP>24</SP> of 22À2 (C = 1À01, H 2 O) and is characterized by (a) a u.v. spectrum as indicated in Fig. 1 (not shown), (b) an infra-red spectrum as indicated in Fig. 2 (not shown) and (e) an nmr spectrum as indicated in Fig. 3 (not shown). The antibiotic is believed to have the following chemical structure Pharmaceutically non-toxic acid addition salts of the antibiotic may be prepared by known methods. The antibiotic or acid addition salt may be admixed with an inert carrier or diluent to form a pharmaceutical or disinfectant composition.
A method for monitoring a health status of a human subject includes the capturing of medical data concerning the health of the subject at defined intervals using a questionnaire. The questionnaire provides a standard script for data capture. Part of the captured data is constrained to a Likert scale while other data is on a visual analog scale. The captured data further includes an assessment by a physician of health symptoms of the subject. The captured data is input into a computer, provided to an algorithm that is configured to assess a risk of acute heart failure. The risk of acute heart failure is computed using the algorithm and the captured data from a plurality of the defined intervals. In one method, the health status of the subject as being either improved or worsening is output to the physician as a function of a value of the computed risk. In another method, a survival function outcome for the subject is predicted using the output of the algorithm.
Macrophages elicit immune responses to pathogens through induction of inflammatory genes. Here, we examined the role of three variants of the SWI/SNF nucleosome remodeling complex-cBAF, ncBAF, and PBAF-in the macrophage response to bacterial endotoxin (lipid A). All three SWI/SNF variants were prebound in macrophages and retargeted to genomic sites undergoing changes in chromatin accessibility following stimulation. Cooperative binding of all three variants associated with de novo chromatin opening and latent enhancer activation. Isolated binding of ncBAF and PBAF, in contrast, associated with activation and repression of active enhancers, respectively. Chemical and genetic perturbations of variant-specific subunits revealed pathway-specific regulation in the activation of lipid A response genes, corresponding to requirement for cBAF and ncBAF in inflammatory and interferon-stimulated gene (ISG) activation, respectively, consistent with differential engagement of SWI/SNF variants by signal-responsive transcription factors. Thus, functional diversity among SWI/SNF variants enables increased regulatory control of innate immune transcriptional programs, with potential for specific therapeutic targeting.
UNLABELLED: Recent insights have identified adrenergic (ADRN) and mesenchymal (MES) cell lineages as distinct biologic cell types and T-cell inflammation as a prognostic marker in neuroblastoma. We hypothesized that elucidating unique and overlapping aspects of these biologic features could serve as novel biomarkers for informing ongoing efforts to improve therapeutic approaches for children with high-risk neuroblastoma. We identified lineage-specific, single-stranded super-enhancers to define ADRN and MES specific genes. Publicly available RNA-seq of diagnostic tumor biopsies was used in Discovery and Validation cohorts. Each tumor was assigned a relative MES score and T-cell inflammation (TCI) score. Survival was assessed using the Kaplan-Meier method, and differences were assessed by the log-rank test. Inflammation scores were correlated with MES scores and anticorrelated with MYCN-amplification in both cohorts. Among patients with high-risk, ADRN tumors, those with TCI tumors had superior overall survival to those with non-inflamed tumors. A similar, but nonsignificant, trend was observed in the Validation cohort. Conversely, there was no difference according to TCI status in the MES cohort in either the Discover or Validation cohorts. High-inflammation scores were correlated with improved survival in some patients with high-risk, ADRN but not MES neuroblastoma. Our findings bolster support for further developing T-cell-based and immunotherapy-based approaches for children with high-risk neuroblastoma of varying MES and ADRN expression.
SIGNIFICANCE: Adrenergic (ADRN) and mesenchymal (MES) lineages are distinct biologic cell types in neuroblastoma. We defined ADRN and MES specific genes and found that high-risk, ADRN tumors harboring elevated T-cell inflammation signatures had superior overall survival. Our findings bolster support for further developing immunotherapy-based approaches for children with high-risk neuroblastoma.
PURPOSE: To obtain a medicine containing an erythromycin derivative, having strong IL-5 production suppressing action and useful for treating various kinds of allergic diseases. CONSTITUTION: This IL-5 production suppressor contains 3-O-(2-nitro-3,4,5,6- tetrafluoro)phenyl-5-O-de sosaminyl-6-O-methylerythronolide A or its acid addition salt as an active ingredient. The compound is further, properly blended with a conventional vehicle, a binder, a lubricant, a disintegrator, etc., and the blend is prepared in oral or parenteral administration form by an ordinary method. The compound is administered at a daily dose of 50-200mg/adult in 2-3 divided portions. The erthromycin A derivative is obtained by reacting 5-O- desosaminyl-6-O-methylerythronolide A in a solvent (e.g. THF) and reacting the compound with pentafluoronitrobenzene in the presence of a base (e.g. NaOH).
INTRODUCTION: The present study aimed to identify the morphological differences in cranial and dentofacial structures between individuals with mouth-breathing and nasal-breathing.
MATERIALS AND METHODS: The study included 120 individuals, 60 each in the nasal breathing (NB) and mouth breathing (MB) groups. 3D stereophotogrammetry, lateral cephalometric radiographs, and intraoral examination results were recorded by the researchers to determine the morphological differences between the MB group and the NB group. The study utilized cephalometric radiographs for 2D hard tissue measurements and 3D stereophotogrammetric records for linear and angular measurements.
RESULTS: Statistically significant differences were found between the NB and MB groups' SNB angles (respectively, 79.3 ± 3.04, 76.6 ± 4.24, and p=0.002). Also, the NB group's SN-GoGn angle was lower than the MB group's (respectively, 31.5 ± 5.12, 36.0 ± 5.55, and p=0.002). Considering the Jarabak ratio, the NB group's Jarabak ratio was higher than the MB group (respectively,65.7 ± 4.16, 62.6 ± 4.10, and p=0.014). In 3D stereophotogrammetry measurements, increased Li-Me' was detected in the MB group than in NB group.
CONCLUSION: Mouth breathing results in significant morphological differences that affect the development of both soft tissues and skeletal structures. Orthodontists utilize these characteristic features observed in mouth-breathing anomalies for early diagnosis and consider referring their patients for medical treatment of mouth breathing.
PURPOSE: Adults who stutter are at risk of developing high levels of social anxiety, leading to negative outcomes and contributing towards stuttering relapse post treatment. To ensure that psychological treatments for social anxiety in stuttering adults are relevant and effective, a broader empirical understanding of the mechanisms of social anxiety in stuttering populations is required. Four key cognitive processing biases identified as maintenance factors in cognitive behavioral models of social anxiety were examined: self-focused attention, safety behavior use, negative self-imagery, and interpretation bias.
METHODS: Adults who stutter and non-stuttering adults (N = 186) were assessed via an online survey. Participants were categorised into two groups based on stuttering: formally diagnosed stuttering and non-stuttering. Within those groups, participants were further categorised as having low or high levels of social anxiety. Cognitive processing bias was assessed in response to two hypothetical social scenarios (i.e., social interaction and social performance).
RESULTS: As predicted, in both adults who stutter and who are non-stuttering, high social anxiety was related to greater self-focused attention, safety behavior use and negative self-imagery compared to low social anxiety. No significant effect of social anxiety or stuttering was found in relation to interpretation bias. A significant effect of social anxiety upon negative self-imagery was observed in formally-diagnosed adults who stutter compared to non-stuttering adults.
CONCLUSION: The results support the use of cognitive behavioral models of social anxiety as a framework for research and treatment development within stuttering populations.
The present disclosure is drawn to oral pharmaceutical compositions and dosage forms containing select testosterone esters and related methods. In one embodiment of the present invention, an oral pharmaceutical composition for administration to subjects in need of testosterone is provided. The composition comprises a testosterone ester and a pharmaceutically acceptable carrier. The testosterone ester can have the structure wherein R is -C 13 H 25 O or -C 14 H 27 O. One or both of the esters can be present in the pharmaceutical composition. The composition is formulated such that upon single dose administration to a group of human subject, the composition provides a mean serum testosterone C avg t12-t24  that is within about 35% to about 70% of the mean serum testosterone C avg t0-t24.
The present invention relates to a novel natural extraction method for cannabinoid without using any additives, alcohol, or butane. The method is configured to extract sap from the cannabis via high-pressure, heated water rather than butane or alcohol. More specifically, natural ingredients such as calcium, magnesium, organic citrus, and mint are used and mixed together with cannabis strain in a coffee filter or cheese cloth filter for heating in water. The water, having the ingredients positioned and packaged similar to a tea bag therein, is either boiled for two hours in a crockpot or for seven minutes in a pressure cooker for providing sap and bud of cannabis. In some embodiments, the cannabis strain is dried and grinded before mixing with other ingredients. The method offers a way to extract cannabinoids swiftly and easily for making cannabis edibles.
A method, computer program product, and computer system for providing medication to a patient in a time slot. The method includes determining a dissolution profile of the patient. The dissolution profile includes a drug dissolution rate of the first drug prescribed to the patient and a filler dissolution rate of the filler selected such that a time gap elapses after the first drug before the second drug is provided. The drug dissolution rate and the filler dissolution rate are patient specific. The method includes sizing the first medicament to correspond to a prescribed dose of the first medicament and sizing the filler to correspond to a time gap. The method includes providing a pill including at least a first medicament and a fill, the first medicament surrounding the fill such that the first medicament dissolves before the fill dissolves.
The investigators are recruiting participants aged 55+ with normal memory who have or had a close family member with Alzheimer's disease. 200 participants will undergo a blood test and a subset will undergo an amyloid PET scan and only 50 participants who have cerebral amyloid deposits will continue in the study. Neither the participant nor the investigators will know whether the participant is receiving sham or active stimulation. Participants will use the device for 12 months at home, for 60 minutes each day when they are awake. Participants will come to the Massachusetts General Hospital in Boston for 4-6 visits: before starting the stimulation, at 6 months, and after 12 months of usage. The participants will undergo PET scans, MRI, EEG, blood tests and memory tests and questionnaires at each visit to monitor progress. In addition, people may elect to allow for us to study their cerebral spinal fluid. Participants will also wear a "fitbit" like watch to monitor sleep and activity throughout the study. The goal of this study is to evaluate whether stimulation with our device at 40Hz will reduce AD pathology in the brain.
In the intervention group, after cesarean delivery in the operating room, maternal vital signs and the newborn's 1st and 5th minute Apgar Score will be evaluated. After the newborn baby is aspirated if necessary, dried with a green cover under the radiant warmer, tied the diaper, and put on a hat, the newborn with an Apgar Score ≥7 and vital signs stable will be wrapped in pre-warmed operating room covers. After providing a suitable environment, the newborn whose body temperature is stabilized will be placed in the prone position without any covering and clothing on the chest area of the mother, and the ALPS value will be applied for about 3 minutes due to the application of hospital procedures, the intramuscular injection will be applied and the ALPS score will be evaluated again after the injection.
The present invention relates to a method for increasing the therapeutic benefit of an antibody to a subject. The benefit of the improvement is typically mediated by an increase in antibody-dependent cell-mediated cytotoxicity (ADCC) of the antibody. The method comprises the following steps: (a) administering to the subject an immunotherapeutic composition comprising a component of an immune system checkpoint or an immunogenic fragment of the component; and (b) also administering the antibody to the subject. The increase in therapeutic benefit to the subject may relate to any disease for which the antibody has a prophylactic or therapeutic effect. The disease may be cancer. The invention also relates to said immunotherapeutic composition and said antibody and to a kit comprising them.
General: In urinary retention, if the sphincter fails to relax as bethanechol contracts the bladder, urine may be forced up the ureter into the kidney pelvis. If there is bacteriuria, this may cause reflux infection.

Information for Patients: Bethanechol chloride tablets should preferably be taken one hour before or two hours after meals to avoid nausea or vomiting. Dizziness, lightheadedness or fainting may occur, especially when getting up from a lying or sitting position.

Drug Interactions: Special care is required if this drug is given to patients receiving ganglion blocking compounds because a critical fall in blood pressure may occur. Usually, severe abdominal symptoms appear before there is such a fall in the blood pressure.

Carcinogenesis, Mutagenesis, Impairment of Fertility: Long-term studies in animals have not been performed to evaluate the effects upon fertility, mutagenic or carcinogenic potential of bethanechol chloride.

Pregnancy: Teratogenic Effects: Pregnancy Category C. Animal reproduction studies have not been conducted with bethanechol chloride. It is also not known whether bethanechol chloride can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Bethanechol chloride should be given to a pregnant woman only if clearly needed.

Nursing Mothers: It is not known whether this drug is secreted in human milk. Because many drugs are secreted in human milk and because of the potential for serious adverse reactions from bethanechol chloride in nursing infants, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.

Pediatric Use: Safety and effectiveness in pediatric patients have not been established.
The astaxanthin group received 12 mg/day of astaxanthin. Each capsule contained 6 mg of astaxanthin and sunflower oil, and each subject ingested one capsule in the morning and one in the evening.